Yuanshang Bio to List on OTC Market in Early June, Aims for One Licensing Deal Per Year Within Three Years
Yuanshang Bio, a new drug company, announced its upcoming listing on the over-the-counter market in early June and aims to secure at least one licensing agreement annually within the next three years. It focuses on developing bispecific antibody new drugs for ophthalmology and oncology.
📋 Article Processing Timeline
- 📰 Published: May 12, 2026 at 21:34
- 🔍 Collected: May 12, 2026 at 22:02 (27 min after Published)
- 🤖 AI Analyzed: May 13, 2026 at 04:56 (6h 54m after Collected)
Central News
(Central News Agency reporter He Hsiu-ling, Taipei, 12th) New drug company Yuanshang Bio is expected to be listed on the over-the-counter market in early June. Yuanshang Bio General Manager Ho Cheng-hung stated that focusing on core assets such as the bispecific antibody new drugs IBI302 for ophthalmology and AP505 for oncology, these have already become licensing and commercialization targets of market attention. Benefiting from the advancement of new drug R&D progress, the goal is to complete at least one licensing deal per year within the next three years, starting this year.
Yuanshang Bio held a media exchange meeting today to explain the progress of its core products and international market layout. Among them, IBI302 targets the markets for wet age-related macular degeneration and diabetic macular edema. It completed its Phase III clinical trial's primary efficacy endpoint in March this year and will subsequently advance toward drug application and international market layout.
Another core product, AP505, is a PD-L1 × VEGF bispecific antibody. Its Greater China rights were licensed to China's Tasly Pharmaceutical Group in 2019, and it is currently advancing through Phase II clinical trials in China.
He stated that Yuanshang Bio has independently established the T-cube bispecific antibody platform, and currently has advanced multiple proprietary products such as AP203, AP402, and AP601. Among them, AP203 is a bispecific antibody product independently developed in Taiwan and undergoing clinical trials in Taiwan; AP402 and AP601 have moved to Australia for clinical development, demonstrating the company's integrated independent R&D capabilities from antibody design, screening, CMC (chemistry, manufacturing, and control) process to clinical development.
In addition to the oncology field, he stated that Yuanshang Bio recently announced a collaboration with U.S. Delos Capital to jointly enter the autoimmune disease market, planning for areas with high unmet medical needs such as atopic dermatitis. This reflects the gradual expansion of global bispecific antibody applications from the oncology field to the autoimmune disease market. (Editor: Chang Chun-mao) 1150512
Choose to stand with facts, every sponsorship you make is a force to protect press freedom.
Download Central News Agency's "First-hand News" APP to grasp the latest news instantly.
The text, pictures, and audio/video on this website may not be reproduced, publicly broadcast, publicly transmitted, or used without authorization.
(Central News Agency reporter He Hsiu-ling, Taipei, 12th) New drug company Yuanshang Bio is expected to be listed on the over-the-counter market in early June. Yuanshang Bio General Manager Ho Cheng-hung stated that focusing on core assets such as the bispecific antibody new drugs IBI302 for ophthalmology and AP505 for oncology, these have already become licensing and commercialization targets of market attention. Benefiting from the advancement of new drug R&D progress, the goal is to complete at least one licensing deal per year within the next three years, starting this year.
Yuanshang Bio held a media exchange meeting today to explain the progress of its core products and international market layout. Among them, IBI302 targets the markets for wet age-related macular degeneration and diabetic macular edema. It completed its Phase III clinical trial's primary efficacy endpoint in March this year and will subsequently advance toward drug application and international market layout.
Another core product, AP505, is a PD-L1 × VEGF bispecific antibody. Its Greater China rights were licensed to China's Tasly Pharmaceutical Group in 2019, and it is currently advancing through Phase II clinical trials in China.
He stated that Yuanshang Bio has independently established the T-cube bispecific antibody platform, and currently has advanced multiple proprietary products such as AP203, AP402, and AP601. Among them, AP203 is a bispecific antibody product independently developed in Taiwan and undergoing clinical trials in Taiwan; AP402 and AP601 have moved to Australia for clinical development, demonstrating the company's integrated independent R&D capabilities from antibody design, screening, CMC (chemistry, manufacturing, and control) process to clinical development.
In addition to the oncology field, he stated that Yuanshang Bio recently announced a collaboration with U.S. Delos Capital to jointly enter the autoimmune disease market, planning for areas with high unmet medical needs such as atopic dermatitis. This reflects the gradual expansion of global bispecific antibody applications from the oncology field to the autoimmune disease market. (Editor: Chang Chun-mao) 1150512
Choose to stand with facts, every sponsorship you make is a force to protect press freedom.
Download Central News Agency's "First-hand News" APP to grasp the latest news instantly.
The text, pictures, and audio/video on this website may not be reproduced, publicly broadcast, publicly transmitted, or used without authorization.